Characterization of trans-resveratrol-loaded lipid-core nanocapsules and tissue distribution studies in rats

Journal of Biomedical Nanotechnology

Volumn 6, Issue 6, 2010, Pages 694-703

  Frozza, Rudimar L ^a   Bernardi, Andressa ^a   Paese, Karina ^a   Hoppe, Juliana B ^a   Da Silva, Thaline ^a   Battastini, Ana M O ^a   Pohlmann, Adriana R ^a,b   Guterres, Sílvia S ^a   Salbego, Christianne ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Biodistribution; Drug delivery; Nanocapsule; Physical stability; Trans Resveratrol

Indexed keywords

ALZHEIMER'S DISEASE; BIODISTRIBUTIONS; BIOLOGICAL ACTIVITIES; BRAIN TISSUE; CYCLOOXYGENASES; ENCAPSULATION EFFICIENCY; INTRAPERITONEAL; MEAN DIAMETER; PHYSICAL CHANGES; PHYSICAL STABILITY; POLYDISPERSITY INDICES; TARGET ORGANS; TISSUE DISTRIBUTIONS; TRANS-RESVERATROL;

ANIMALS; BIOCHEMISTRY; BRAIN; DISEASES; DRUG DELIVERY; ENCAPSULATION; PARTICLE SIZE; POLYDISPERSITY; RATS; TISSUE; ZETA POTENTIAL;

NANOCAPSULES;

LIPID CORE NANOCAPSULE; NANOCAPSULE; RESVERATROL; UNCLASSIFIED DRUG; ANTIOXIDANT; LIPID; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; DRUG BRAIN LEVEL; DRUG EFFECT; DRUG LIVER LEVEL; DRUG SAFETY; DRUG TOLERABILITY; ENCAPSULATION; KIDNEY; MALE; NONHUMAN; PARTICLE SIZE; RAT; TISSUE DISTRIBUTION; ZETA POTENTIAL; ANIMAL; CHEMISTRY; DRUG STABILITY; GASTROINTESTINAL TRACT; PH; WISTAR RAT;

ANIMALS; ANTIOXIDANTS; DRUG STABILITY; GASTROINTESTINAL TRACT; HYDROGEN-ION CONCENTRATION; LIPIDS; MALE; NANOCAPSULES; RATS; RATS, WISTAR; STILBENES;

EID: 79953020260     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2010.1161     Document Type: Article

References (39)

1. J. A. Baur and D. A. Sinclair, Therapeutic potential of resveratrol: The in vivo evidence. Nat. Rev. Drug Discov. 5, 493 (2006).
2. M. E. Juan, M. P. Vinardell, and J. M. Planas, The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful. J. Nutr. 132, 257 (2002).
3. G. J. Soleas, E. P. Diamandis, and D. M. Goldberg, Resveratrol: A molecule whose time has come? And gone? Clin. Biochem. 30, 91 (1997).
4. W. Andlauer, J. Kolb, K. Siebert, and P. Fürst, Assessment of resveratrol bioavailability in the perfused small intestine of the rat. Drug Exptl. Clin. Res. XXVI, 47 (2000).
5. G. Kuhnle, J. P. E. Spencer, G. Chowrimootoo, H. Schroeter, E. S. Debnam, S. K. S. Srai, C. Rice-Evans, and U. Hahn, Resveratrol is absorbed in the small intestine as resveratrol glucuronide. Biochem. Biophys. Res. Comm. 272, 212 (2000).
6. Z. Piñeiro, M. Palma, and C. G. Barroso, Determination of transresveratrol in grapes by pressurised liquid extraction and fast high-performance liquid chromatography. J. Chromatogr. A 1110, 61 (2006).
7. A. A. E. Bertelli, L. Giovannini, R. Stradi, S. Urien, J. P. Tillement, and A. Bertelli, Kinetics of trans- and cis-resveratrol (3,4,5- trihydroxystilbene) after red wine oral administration in rats. Int. J. Clin. Pharmacol. Res. 16, 77 (1996).
8. T. Walle, F. Hsieh, M. H. DeLegge, J. E. Oatis, Jr., and U. K. Walle, High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 32, 1377 (2004).
9. E. Wenzel and V. Somoza, Metabolism and bioavailability of transresveratrol. Mol. Nutr. Food Res. 49, 472 (2005).
10. M. L. Hans and A. M. Lowman, Biodegradable nanoparticles for drug delivery and targeting. Curr. Opin. Solid. State Mater. Sci. 6, 319 (2002).
11. P. Couvreur, G. Barratt, E. Fattal, P. Legrand, and C. Vauthier, Nanocapsule Technology: A review. Crit. Rev. Ther. Carrier Syst. 19, 99 (2002).
12. D. J. Begley, Delivery of therapeutic agents to the central nervous system: The problems and the possibilities. Pharmacol. Ther. 104, 29 (2004).
13. E. Allémann, J. C. Leroux, and R. Gurny, Polymeric nano- and microparticles for the oral delivery of peptides and peptidomimetics. Adv. Drug Del. Rev. 34, 171 (1998).
14. H. Pinto-Alphandary, A. Andremont, and P. Couvreur, Targeted delivery of antibiotics using liposomes and nanoparticles: Research and applications. Int. J. Antimicrob. Agents 13, 155 (2000).
15. S. S. Guterres, C. B. Muller, C. B. Michalowski, A. R. Pohlmann, and T. Dalla Costa, Gastro-intestinal tolerance after oral administration of spray-dried diclofenac-loaded nanocapsules and nanospheres. S.T.P. Pharma Sci. 11, 229 (2001).
16. A. Vila, A. Sanchez, M. Tobio, P. Calvo, and M. J. Alonso, Design of biodegradable particles for protein delivery. J. Controlled Release 78, 15 (2002).
17. A. Bernardi, E. Braganhol, E. Jäger, F. Figueiró, M. I. Edelweiss, A. R. Pohlmann, S. S. Guterres, and A. M. O. Battastini, Indomethacin-loaded nanocapsules treatment reduces I glioblastoma growth in a rat glioma model. Cancer Lett. 281, 53 (2009a).
18. A. Bernardi, A. C. Zilberstein, E. Jäger, M. M. Campos, F. B. Morrone, J. P. Calixto, A. R. Pohlmann, S. S Guterres, and A. M. O. Battastini, Effects of indomethacin-loaded nanocapsules in experimental model of inflammation in rats. Br. J. Pharmacol. 158, 1104 (2009b).
19. E. Jäger, C. G. Venturini, F. S. Poletto, L. M. Colomé, J. P. U. Pohlmann, A. Bernardi, A. M. O. Battastini, S. S. Guterres, and A. R. Pohlmann, Sustained release from lipid-core nanocapsules by varying the core viscosity and the particle surface area. J. Biomed Nanotech. 5, 130 (2009).
20. O. Mengual, G. Meunier, I. Cayre, K. Puech, and P. Snabre, Characterization of instability of concentrated dispersions by a new optical analyser: The TURBISCAN MA 1000. Colloid and Surface A 152, 111 (1999a).
21. O. Mengual, G. Meunier, I. Cayre, K. Puech, and P. Snabre, TURBISCAN MA 2000: Multiple light scattering measurements for concentrated emulsion and suspension instability analysis. Talanta 50, 445 (1999b).
22. S. R. Schaffazick, A. R. Pohlmann, C. A. S. de Cordova, T. B. Creczynski-Pasa, and S. S. Guterres, Protective properties of melatonin-loaded nanoparticles against lipid peroxidation. Int. J. Pharm. 289, 209 (2005).
23. A. F. Ourique, A. R. Pohlmann, S. S. Guterres, and R. C. R. Beck, Tretinoin-loaded nanocapsules: Preparation, physicochemical characterization, and photostability study. Int. J. Pharm. 352, 1 (2008).
24. B. Wilson, M. K. Samanta, K. Santhi, K. P. S. Kumar, N. Paramakrishnan, and B. Suresh, Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the target delivery of rivastigmine into the brain to treat Alzheimer's disease. Brain Res. 1200, 159 (2008).
25. J. A. Baur, K. J. Pearson, N. L. Price, H. A. Jamieson, C. Lerin, A. Kalra, V. V. Prabhu, J. S. Allard, G. Lopez-Lluch, K. Lewis, P. J. Pistell, S. Poosala, K. G. Becker, O. Boss, D. Gwinn, M. Wang, S. Ramaswamy, K. W. Fishbein, R. G. Spencer, E. G. Lakatta, D. Le Couteur, R. J. Shaw, P. Navas, P. Puigserver, D. K. Ingram, R. de Cabo, and D. A. Sinclair, Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444, 337 (2006).
26. M. E. Juan, M. Maijó, and J. M. Planas, Quantification of transresveratrol and its metabolites in rat plasma and tissues by HPLC. J. Pham. Biomed. Anal. 51, 391 (2009).
27. 3H]trans- resveratrol in rat tissues following oral administration, Br. J. Nutr. 96, 62 (2006).
28. J.-F. Marier, P. Vachon, A. Gritsas, J. Zhang, J.-P. Moreau, and M. P. Ducharme, Metabolism and disposition of resveratrol in rats: Extent of absorption, glucoronidation, and enterohepatic recirculation evidenced by a linked-rat model. J. Pharmacol. Exp. Ther. 302, 369 (2002).
29. X. Meng, P. Maliakal, H. Lu, M.-J. Lee, and C. S. Yang, Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J. Agric. Food Chem. 52, 935 (2004).
30. L. Grislain, P. Couvreur, V. Lenaerts, M. Roland, D. Deprez-Decampeneere, and P. Speiser, Pharmacokinetics and distribution of a biodegradable drug-carrier. Int. J. Pharm. 15, 335 (1983).
31. V. Lenaerts, J. F. Nagelkerke, T. J. Van Berkel, P. Couvreur, L. Grislain, M. Roland, P. Speiser, In vivo uptake of polyisobutyl cyanoacrylate nanoparticles by rat liver Kupffer, endothelial, and parenchymal cells. J. Pharm. Sci. 73, 980 (1984a).
32. V. Lenaerts, P. Couvreur, D. Christiaens-Leyh, E. Joirs, M. Roland, B. Rollman, and P. Speiser, Degradation of ply(isobutyl cyanoacrylate) nanoparticles. Biomaterials 5, 65 (1984b).
33. J. Kreuter, R. N. Alyautdin, D. A. Kharkevich, and A. A. Ivanov, Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res. 67A, 171 (1995).
34. R. N. Alyautdin, V. E. Petrov, K. Langer, A. Berthold, D. A. Kharkevich, and J. Kreuter, Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated poly(butylcyanoacrylate) nanoparticles. Pharm. Res. 14, 325 (1997).
35. A. E. Gulyaev, S. E. Gelperina, I. N. Skidan, A. S. Antropov, G. Y. Kivman, and J. Kreuter, Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm. Res. 16, 1564 (1999).
36. M. Shakweh, G. Ponchel, and E. Fattal, Particle uptake by Peyer's patches: A pathway for drug and vaccine delivery. Expert Opin. Drug Deliv. 1, 141 (2004).
37. C. Prego, M. Garcia, D. Torres, and M. J. Alonso, Transmucosal macromolecular drug delivery. J. Controlled Release 101, 151 (2005).
38. J. Martinez and J. J. Moreno, Effect of resveratrol, a natural polyphenols compound, on reactive oxygen species and prostaglandin production. Biochem. Pharmacol. 59, 865 (2000).
39. L. M. Szewczuk, L. Forti, L. A. Stivala, T. M. Penning, Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2: A mechanistic approach to the designs of COX-1 selective agents. J. Biol. Chem. 279, 22727 (2004).